Pharmacoepidemiological assessment of drug interactions with vitamin K antagonists

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 11, 2014, Pages 1160-1167

  Pottegård, Anton ^a,b   dePont Christensen, Rene ^a   Wang, Shirley V ^c   Gagne, Joshua J ^c   Larsen, Torben B ^d,e   Hallas, Jesper ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY   (Denmark)

Author keywords

Denmark; Drug drug interactions; Pharmacoepidemiology; Self controlled case series; Vitamin K antagonists; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; CODEINE; NARCOTIC ANALGESIC AGENT; PHENPROCOUMON; PRESCRIPTION DRUG; TRAMADOL; VITAMIN K GROUP; WARFARIN;

AGE; AGED; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; DENMARK; DRUG INTERACTION; FEMALE; HUMAN; INSURANCE; INTERNATIONAL NORMALIZED RATIO; MALE; PHARMACOEPIDEMIOLOGY; SEX DIFFERENCE; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; CODEINE; DENMARK; DRUG INTERACTIONS; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; INTERNATIONAL NORMALIZED RATIO; MALE; PHARMACOEPIDEMIOLOGY; PHENPROCOUMON; PRESCRIPTION DRUGS; SEX FACTORS; TRAMADOL; VITAMIN K; WARFARIN;

EID: 84920276076     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3714     Document Type: Article

References (31)

1. Steffensen FH, Kristensen K, Ejlersen E, Dahlerup JF, Sørensen HT. Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. Journal of Internal Medicine 1997; 242: 497-503.
2. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428.
3. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ Can Med Assoc J J Assoc Medicale Can 2008; 179: 235-244. doi:10.1503/cmaj.080171.
4. Veeger NJGM, Piersma-Wichers M, Tijssen JGP, Hillege HL, van der Meer J. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. British Journal of Haematology 2005; 128: 513-519. doi:10.1111/j.1365-2141.2004.05348.x.
5. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. AMA Archives of Internal Medicine 2005; 165: 1095-1106. doi:10.1001/archinte.165.10.1095.
6. Jobski K, Behr S, Garbe E. Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database. European Journal of Clinical Pharmacology 2011; 67: 941-951. doi:10.1007/s00228-011-1031-6.
7. Abarca J, Malone DC, Armstrong EP, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc JAPhA 2004; 44: 136-141.
8. Madsen H, Rasmussen JM, Brøsen K. Interaction between tramadol and phenprocoumon. Lancet 1997; 350: 637. doi:10.1016/S0140-6736(05)63325-9.
9. Boeijinga JK, van Meegen E, van den Ende R, Schook CE, Cohen AF. Lack of interaction between tramadol and coumarins. Journal of Clinical Pharmacology 1998; 38: 966-970.
10. Meegaard PM, Holck LHV, Pottegård A, Madsen H, Hallas J. Excessive anticoagulation with warfarin or phenprocoumon may have multiple causes. Dan Med J 2012; 59: A4383.
11. Pottegård A, Meegaard PM, Holck LHV, Christensen R. dePont, Madsen H, Hallas J. Concurrent use of tramadol and oral vitamin K antagonists and the risk of excessive anticoagulation: a register-based nested case-control study. European Journal of Clinical Pharmacology 2013; 69: 641-646. doi:10.1007/s00228-012-1363-x.
12. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Danish Medical Bulletin 1997; 44: 445-448.
13. WHO Collaborating Centre for Drug Statistics methodology. Guidelines for ATC classification and DDD assignment, Oslo: Norway, 2013; 2012.
14. Pedersen CB. The Danish Civil Registration System. Scandinavian Journal of Public Health 2011; 39: 22-25. doi:10.1177/1403494810387965.
15. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995; 345: 567-569.
16. Hallas J, Pottegård A. Use of self-controlled designs in pharmacoepidemiology. Pharmacoepidemiology and Drug Safety 2013; 22(8): 803-809. doi:10.1111/joim.12186.
17. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Statistics in Medicine 2006; 25: 1768-1797. doi:10.1002/sim.2302.
18. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. American Journal of Epidemiology 1991; 133: 144-153.
19. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696. doi:10.1161/CIRCULATIONAHA.106.653048.
20. Palareti G, Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thrombosis and Haemostasis 2009; 102: 268-278. doi:10.1160/TH08-11-0730.
21. About the self-controlled case series method. Available at: http://statistics.open.ac.uk/sccs. Accessed February 17, 2014.
22. Hallas J, Christensen RD, Stürmer T, Pottegård A. Measures of "exposure needed for one additional patient to be harmed" in population-based case-control studies. Pharmacoepidemiology and Drug Safety 2014; 23(8): 868-874. doi:10.1002/pds.3635.
23. Thygesen LC, Daasnes C, Thaulow I, Brønnum-Hansen H. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scandinavian Journal of Public Health 2011; 39: 12-16.
24. Scher ML, Huntington NH, Vitillo JA. Potential interaction between tramadol and warfarin. Annals of Pharmacotherapy 1997; 31: 646-647.
25. Sabbe JR, Sims PJ, Sims MH. Tramadol-warfarin interaction. Pharmacotherapy 1998; 18: 871-873.
26. Dumo PA, Kielbasa LA. Successful anticoagulation and continuation of tramadol therapy in the setting of a tramadol-warfarin interaction. Pharmacotherapy 2006; 26: 1654-1657. doi:10.1592/phco.26.11.1654.
27. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clinical Pharmacokinetics 2005; 44: 1227-1246. doi:10.2165/00003088-200544120-00003.
28. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. British Medical Journal 2006; 333: 726. doi:10.1136/bmj.38947.697558.AE.
29. Penning-van Beest FJA, Geleijnse JM, van Meegen E, Vermeer C, Rosendaal FR, Stricker BHC. Lifestyle and diet as risk factors for overanticoagulation. Journal of Clinical Epidemiology 2002; 55: 411-417.
30. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-198S. doi:10.1378/chest.08-0670.
31. Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. An update. Clinical Pharmacokinetics 1996; 30: 416-444.